Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Other Accumulated Expenses (2020 - 2025)

Tango Therapeutics (TNGX) has 6 years of Other Accumulated Expenses data on record, last reported at $1.3 million in Q4 2025.

  • For Q4 2025, Other Accumulated Expenses fell 25.71% year-over-year to $1.3 million; the TTM value through Dec 2025 reached $1.3 million, down 25.71%, while the annual FY2025 figure was $1.3 million, 25.71% down from the prior year.
  • Other Accumulated Expenses reached $1.3 million in Q4 2025 per TNGX's latest filing, down from $1.7 million in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $1.7 million in Q4 2024 and bottomed at $666000.0 in Q4 2021.
  • Average Other Accumulated Expenses over 5 years is $1.3 million, with a median of $1.3 million recorded in 2023.
  • Peak YoY movement for Other Accumulated Expenses: surged 90.24% in 2022, then dropped 25.71% in 2025.
  • A 5-year view of Other Accumulated Expenses shows it stood at $666000.0 in 2021, then soared by 90.24% to $1.3 million in 2022, then increased by 1.58% to $1.3 million in 2023, then soared by 34.81% to $1.7 million in 2024, then dropped by 25.71% to $1.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Accumulated Expenses were $1.3 million in Q4 2025, $1.7 million in Q3 2025, and $1.7 million in Q4 2024.